Phosphorylated Tau Levels in Donated Blood (NCT07157839) | Clinical Trial Compass
RecruitingNot Applicable
Phosphorylated Tau Levels in Donated Blood
United States250 participantsStarted 2025-08-28
Plain-language summary
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The plasma sample from donators.
Exclusion Criteria:
* None.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is measuring levels of phosphorylated tau — especially pTau217 — in donated blood samples; could my doctor explain what pTau217 is and why its concentration in blood might be meaningful for understanding Alzheimer's disease?
2Since this trial is listed as 'Phase NA,' it seems to be a blood collection or observational study rather than a treatment trial — can my doctor clarify whether participating would involve any intervention, or would I simply be donating a blood sample?
3Given that this study appears to be measuring tau biomarkers rather than testing a therapy, would the results of my donated sample ever be shared with me or my care team, and could they inform my own diagnosis or care plan in any way?
4Are there any risks or considerations I should know about before deciding whether to donate blood for this kind of research, even if the study itself seems low-risk?
5My doctor knows my full medical history — given where I am in my Alzheimer's diagnosis, would participating in this biomarker research study be compatible with any other treatments or clinical trials I might want to pursue at the same time?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Tau and pTau
Timeframe: 6 months.
2
Concentration of pTau217 and Tau
Timeframe: 6 months.
Trial details
NCT IDNCT07157839
SponsorThe University of Texas Health Science Center, Houston